The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 05, 2021

Filed:

Feb. 16, 2017
Applicants:

Yale University, New Haven, CT (US);

Carnegie Mellon University, Pittsburgh, PA (US);

Inventors:

W. Mark Saltzman, New Haven, CT (US);

Peter Glazer, Guilford, CT (US);

Raman Bahal, Hamden, CT (US);

Nicole Ali McNeer, Westport, CT (US);

Danith H. Ly, Pittsburgh, PA (US);

Elias Quijano, New Haven, CT (US);

Assignees:

Yale University, New Haven, CT (US);

Carnegie Mellon University, Pittsburgh, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C12N 15/90 (2006.01); C07K 14/00 (2006.01); C12N 15/10 (2006.01); C12N 15/11 (2006.01); A61K 9/16 (2006.01); A61K 48/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/907 (2013.01); A61K 9/1647 (2013.01); A61K 48/005 (2013.01); C07K 14/003 (2013.01); C12N 15/102 (2013.01); C12N 15/11 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 2310/15 (2013.01); C12N 2310/152 (2013.01); C12N 2310/318 (2013.01); C12N 2310/3181 (2013.01); C12N 2310/334 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3519 (2013.01);
Abstract

Compositions and methods for enhancing targeted gene editing and methods of use thereof are disclosed. In the most preferred embodiments, gene editing is carried out utilizing a gene editing composition such as triplex-forming oligonucleotides, CRISPR, zinc finger nucleases, TALENS, or others, in combination with a gene modification potentiating agent such as stem cell factor (SCF), a CHK1 or ATR inhibitor, or a combination thereof. A particular preferred gene editing composition is triplex-forming peptide nucleic acids (PNAs) substituted at the γ position for increased DNA binding affinity. Nanoparticle compositions for intracellular delivery of the gene editing composition are also provided and particular advantageous for use with in vivo applications.


Find Patent Forward Citations

Loading…